Elizabeth Grammer - Ardelyx Vice President General Counsel
| ARDX Stock | USD 6.46 0.04 0.62% |
President
Ms. Elizabeth Grammer, Esq. is Senior Vice President, General Counsel of the Company. She has served as our General Counsel since May 2014 and formerly served as our vice president responsible for legal affairs from December 2012 until May 2014. From 2006 to December 2012, Ms. Grammer served as an independent outside corporate counsel for public and private biotechnology companies, including Ardelyx from January 2010 until December 2012. From 2001 to 2006, Ms. Grammer served as Vice President and General Counsel of Trine Pharmaceuticals, Inc., a biopharmaceutical company. In addition, Ms. Grammer previously served as independent outside corporate counsel to GelTex Pharmaceuticals, a biopharmaceutical company since 2014.
| Age | 60 |
| Tenure | 10 years |
| Address | 400 Fifth Avenue, Waltham, MA, United States, 02451 |
| Phone | 510 745 1700 |
| Web | https://www.ardelyx.com |
Elizabeth Grammer Latest Insider Activity
Tracking and analyzing the buying and selling activities of Elizabeth Grammer against Ardelyx stock is an integral part of due diligence when investing in Ardelyx. Elizabeth Grammer insider activity provides valuable insight into whether Ardelyx is net buyers or sellers over its current business cycle. Note, Ardelyx insiders must abide by specific rules, including filing SEC forms every time they buy or sell Ardelyx'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Elizabeth Grammer over a month ago Disposition of 86000 shares by Elizabeth Grammer of Ardelyx at 7.7323 subject to Rule 16b-3 |
Ardelyx Management Efficiency
The company has return on total asset (ROA) of (0.1622) % which means that it has lost $0.1622 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4984) %, meaning that it created substantial loss on money invested by shareholders. Ardelyx's management efficiency ratios could be used to measure how well Ardelyx manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.23 in 2024. Return On Capital Employed is likely to drop to -0.27 in 2024. At this time, Ardelyx's Non Current Assets Total are fairly stable compared to the past year. Non Currrent Assets Other is likely to rise to about 47.1 M in 2024, whereas Total Assets are likely to drop slightly above 180.1 M in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| Joseph Lobacki | Verastem | 59 | |
| Jeffrey Wade | Lexicon Pharmaceuticals | 53 | |
| Michael Ferraresso | Verastem | N/A | |
| Gary Branch | Lexicon Pharmaceuticals | N/A | |
| James Tessmer | Lexicon Pharmaceuticals | 58 | |
| Erin MD | Terns Pharmaceuticals | 53 | |
| Thomas DesRosier | Seres Therapeutics | 63 | |
| Michele Trucksis | Seres Therapeutics | 64 | |
| Erik MBA | AVROBIO | 52 | |
| Moshe Phillip | BioLineRx | 62 | |
| Monica Kleinman | Verastem | 35 | |
| Alyssa Wyant | PDS Biotechnology Corp | 42 | |
| Jeffrey JD | Lexicon Pharmaceuticals | 59 | |
| Abi VainsteinHaras | BioLineRx | 41 | |
| Robert Lisicki | Zura Bio Limited | 56 | |
| Holly MBA | BioLineRx | 62 | |
| Arnon Aharon | BioLineRx | N/A | |
| Praveen Tyle | Lexicon Pharmaceuticals | 57 | |
| David Malek | BioLineRx | 39 | |
| Ella Sorani | BioLineRx | 56 | |
| Birgitte Volck | AVROBIO | 56 | |
Management Performance
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.16 |
Ardelyx Leadership Team
Elected by the shareholders, the Ardelyx's board of directors comprises two types of representatives: Ardelyx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Ardelyx. The board's role is to monitor Ardelyx's management team and ensure that shareholders' interests are well served. Ardelyx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Ardelyx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Paul Korner, Executive Vice President and Chief Medical Officer | ||
| Gordon Ringold, Independent Director | ||
| Robert Bazemore, Independent Director | ||
| Elizabeth Grammer, Vice President General Counsel | ||
| Robert Felsch, Senior Officer | ||
| David Rosenbaum, Sr. VP of Drug Devel. | ||
| Geoffrey Block, Director | ||
| Kimia Keshtbod, Mang Relations | ||
| Richard Rodgers, Independent Director | ||
| Mark Kaufmann, CFO | ||
| Jeremy Caldwell, Chief Scientific Officer and Executive VP | ||
| Karen Harrigan, Director Devel | ||
| Charon Sr, Chief Officer | ||
| Elizabeth Esq, Chief Secretary | ||
| Susan Rodriguez, Chief Officer | ||
| William Bertrand, Independent Director | ||
| Michael Raab, CEO and President and Director | ||
| Bryan Shaw, Chief Accounting Officer, Vice President Controller | ||
| CPA MST, CFO Treasurer | ||
| Caitlin Lowie, Vice Relations | ||
| Robert Blanks, Chief Officer | ||
| Mike Kelliher, Executive Strategy | ||
| Jan Lundberg, Director | ||
| Reginal Seeto, COO, Executive Vice President | ||
| David Mott, Independent Chairman of the Board | ||
| Annalisa Jenkins, Independent Director | ||
| Dan Pavicich, Director Devel | ||
| MPH MD, Chief Officer |
Ardelyx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Ardelyx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.5 | ||||
| Return On Asset | -0.16 | ||||
| Profit Margin | (0.53) % | ||||
| Operating Margin | (0.81) % | ||||
| Current Valuation | 1.39 B | ||||
| Shares Outstanding | 232.69 M | ||||
| Shares Owned By Insiders | 1.94 % | ||||
| Shares Owned By Institutions | 60.24 % | ||||
| Number Of Shares Shorted | 33.93 M | ||||
| Price To Earning | (2.11) X |
Pair Trading with Ardelyx
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Ardelyx position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Ardelyx will appreciate offsetting losses from the drop in the long position's value.Moving together with Ardelyx Stock
| 0.8 | DVAX | Dynavax Technologies Financial Report 7th of May 2024 | PairCorr |
| 0.78 | EGRX | Eagle Pharmaceuticals | PairCorr |
| 0.69 | ELAN | Elanco Animal Health Financial Report 14th of May 2024 | PairCorr |
Moving against Ardelyx Stock
| 0.8 | ACB | Aurora Cannabis Downward Rally | PairCorr |
| 0.8 | CGC | Canopy Growth Corp Downward Rally | PairCorr |
| 0.77 | HCM | HUTCHMED DRC | PairCorr |
| 0.74 | FLGC | Flora Growth Corp Financial Report 20th of May 2024 | PairCorr |
The ability to find closely correlated positions to Ardelyx could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Ardelyx when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Ardelyx - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Ardelyx to buy it.
The correlation of Ardelyx is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Ardelyx moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Ardelyx moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Ardelyx can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Ardelyx. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. For more information on how to buy Ardelyx Stock please use our How to Invest in Ardelyx guide.Note that the Ardelyx information on this page should be used as a complementary analysis to other Ardelyx's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Watchlist Optimization module to optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm.
Complementary Tools for Ardelyx Stock analysis
When running Ardelyx's price analysis, check to measure Ardelyx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ardelyx is operating at the current time. Most of Ardelyx's value examination focuses on studying past and present price action to predict the probability of Ardelyx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ardelyx's price. Additionally, you may evaluate how the addition of Ardelyx to your portfolios can decrease your overall portfolio volatility.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated |
Is Ardelyx's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Ardelyx. If investors know Ardelyx will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Ardelyx listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.30) | Revenue Per Share 0.567 | Quarterly Revenue Growth (0.22) | Return On Assets (0.16) | Return On Equity (0.50) |
The market value of Ardelyx is measured differently than its book value, which is the value of Ardelyx that is recorded on the company's balance sheet. Investors also form their own opinion of Ardelyx's value that differs from its market value or its book value, called intrinsic value, which is Ardelyx's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Ardelyx's market value can be influenced by many factors that don't directly affect Ardelyx's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Ardelyx's value and its price as these two are different measures arrived at by different means. Investors typically determine if Ardelyx is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Ardelyx's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.